Loss of HER2 after HER2-targeted treatment

Breast Cancer Research and Treatment
Tanja IgnatovAtanas Ignatov

Abstract

HER2 expression has been reported to be discordant between primary tumor and metastatic tissue. HER2 discordance and relation to HER2-targeted treatment was investigated in 227 patients with primary breast cancer. HER2 discordance between primary biopsy and second biopsy after neoadjuvant or adjuvant treatment was observed in 20.7%. This discordance was related only to the use of HER2-targeted treatment: 30 of 33 (90.9%) women with downgraded HER2 expression underwent a HER2-targeted therapy, whereas in the group of patients with concordant HER2 expression, only 32 of 180 (17.8%) received HER2-targeted treatment (p < 0.0001). HER2 discordance was associated with reduced disease-free survival but not overall survival. In a second cohort, including patients with HER2 overexpressing tumors, trastuzumab treatment was associated with change of HER2 expression from positive to negative in 47.3% of cases. Addition of pertuzumab increased the rate of HER2 loss up to 63.2%. Notably, the interval between last HER2-targeted treatment and the time of surgical excision of the tumor after neoadjuvant chemotherapy (NACT) or the biopsy of the metachronous metastasis was associated with a significant change in HER2 expression. The median time b...Continue Reading

References

Nov 14, 2001·Seminars in Oncology·J BaselgaJ Arribas
Apr 1, 2005·International Journal of Cancer. Journal International Du Cancer·Karianne E LongvaInger H Madshus
Sep 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael F PressDennis J Slamon
Nov 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth A MittendorfAna M Gonzalez-Angulo
Nov 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Naoki NiikuraNaoto T Ueno
Sep 10, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V GuarneriP F Conte
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Aug 8, 2014·Membranes·Vibeke Bertelsen, Espen Stang
May 1, 2015·Breast Cancer Research and Treatment·Tanja IgnatovAtanas Ignatov
Jul 19, 2015·Endocrine-related Cancer·Holm EggemannAtanas Ignatov
Dec 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·N NiikuraY Tokuda
Mar 25, 2016·Endocrine-related Cancer·Tanja IgnatovAtanas Ignatov
Apr 12, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Renu GahlautAbeer M Shaaban
Nov 6, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Hiroshi SaekiUNKNOWN Kyushu Study Group of Clinical Cancer (KSCC)

❮ Previous
Next ❯

Citations

Sep 25, 2019·Nature Reviews. Clinical Oncology·Do-Youn Oh, Yung-Jue Bang
Aug 5, 2019·Breast Cancer Research and Treatment·Z StrizovaJ Bartunkova
Sep 29, 2020·Frontiers in Immunology·Charita FurumayaHanke L Matlung
Jul 20, 2020·BMC Cancer·Laura Rey-VargasSilvia J Serrano-Gomez
Jun 21, 2020·Journal for Immunotherapy of Cancer·Victoria A BrentvilleLindy G Durrant
Apr 17, 2021·Frontiers in Immunology·Samantha J PastonLindy G Durrant
Apr 22, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ursula WiedermannAnthony J Good

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.